Yelena Y. Janjigian, MD, Considers Immunotherapy Treatment Options for Gastric Cancer

Video

Yelena Y. Janjigian, MD, spoke about using immunotherapy across settings to treat localized gastric cancer.

At the 2022 International Gastric Cancer Conference, Yelena Y. Janjigian, MD, chief of Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, spoke with CancerNetwork® about immunotherapy in the adjuvant and neoadjuvant settings to treat gastric cancer. She also discusses the KEYNOTE-811 trial (NCT03615326), which showed that combining pembrolizumab (Keytruda) plus trastuzumab (Herceptin) and chemotherapy was able to reduce tumor size and lead to complete response in certain patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Transcript:

In the neoadjuvant setting, the field is moving toward [understanding for] which patients we can escalate or deescalate therapy. Most of the interesting studies are focused on patient selection, particularly [with] use of circulating tumor DNA in the adjuvant setting to predict which patients, beyond the tumor stage or the nodal stage, are at a higher risk for recurrence. Those patients can potentially escalate therapy. For neoadjuvant therapy, newer studies are focused on the MSI [microsatellite instability]–high population to understand if perhaps dual immune checkpoint blockade—such as nivolumab [Opdivo] plus ipilimumab [Yervoy], so dual anti–CTLA-4 and anti–PD-1 therapy—may improve [overall] responses and complete responses. Perhaps we can do some organ preservation and not even have surgery in subsets.

Right now, the truth is other novel immunotherapy agents are mostly relegated to the stage IV setting. There’s not enough data to suggest that these newer agents such as TIGIT [T-cell immunoreceptor with Ig and ITIM domains]–directed antibodies, work well enough in the stage IV setting to move it to earlier stages. That’s typically how we do drug development. One of the regimens that possibly is in primetime and ready to develop is for HER2-positive disease, so targeting tumor-specific characteristics such as HER2 and using that to augment the directed therapy using antibodies against PD-1, such as the trastuzumab and pembrolizumab combination. In earlier stage disease, perhaps particularly since the response rate in stage IV disease is so high, we saw 11% complete response rate and 74% partial response in KEYNOTE-811, which is unheard of in this disease.

Reference

Janjigian YY, Kawazoe A, Yañez P, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727-730. doi:10.1038/s41586-021-04161-3

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content